It wouldn't surprise me one bit to see them report next week just before the 2016 Annual Meeting. I really hope they plan on having a Q call and are not expecting people to show up in Minnesota for finer details.
I have not gone shopping yet and would like to wait until I am in size 16. I had been wearing size 1-2X and 20w. But I love that I can breathe in what I am wearing. I will never take that for granted again. This goes to a reward, too, when I look in the mirror and I start seeing the changes, I couldn’t be more pleased with the results.
In an earlier post, I had talked about how my health was one of my great motivators, I didn’t want to feel sick and tired all of the time. I am proud to say I have not used Metformin for 2 months and am not even testing any more. So Diabetes is off the list of aliments! That is huge and I am thrilled!
Looks like Daniel Cohen is no longer with the company. He had been with the company for 7-8 years as Senior Vice President of Government Relations and Health Policy. He was recently hired by KemPharm.
Dan Gladney said they where working towards a smaller device and other indications. Seems to me Daniel Cohen could be a huge loss. I guess there are other scenario's or reasons he could have left, but on the face of it like everything else with the company to date it's a loss.
But I agree with everything you noted.
"We believe that this option exchange program would be in the best interests of our stockholders and EnteroMedics, as the replacement stock options would help us to retain and motivate further our most talented employees so that we can continue to build value for our stockholders. In addition, the option exchange program would reduce the total number of outstanding stock options held by our employees and, because we will incur minimal incremental compensation expense in connection with the option exchange program, allow us to more effectively utilize the compensation expense that we have already recognized in our financial statements in connection with the grants of the existing underwater stock options."
The way this is headlined makes it sound like it is my blog, it is not. I just copied the heading from the blog.
"I decided to Start sharing my journey now that I have had weight loss surgery. I had a new procedure, the VBloc on December 29th. Since starting this journey I have lost about 60 lbs. High mark of 314 (I'm 5'10") now at 255."
April 7th, 2016
LOL. Make up your mind. According to you and others the company will go bankrupt. Yet you think John M. Morton, Sajani N. Shah, Bruce M. Wolfe, Caroline M. Apovian, Christopher J. Miller, Katherine S. Tweden , Charles J. Billington, and Scott A. Shikora would somehow put their careers on the line cooking results/study. Besides, I see only two names on the list who are on ETRM payroll. Also the FDA is closely monitoring vbloc and it's results which they spoke highly of. So if you believe these professionals are willing to stick their necks out on some bogus results knowing good and well how closely the tech is being watched you a bigger fool than you think I am.
I will be here for the buy-out, that is very soothing to know!
The FDA and the Advisory Panel Members where clear "We need to fill the gap between weight loss pills and invasive surgery." Vbloc clearly does that and with the news today it beats out other surgical procedures, some by a mile!
"Results observed in the moderately obese population provide strong support for vBloc Therapy's application within this subgroup of patients, many of whom are not willing to undergo, or not appropriate for, more aggressive surgical interventions," said Scott Shikora, M.D., F.A.C.S., EnteroMedics Executive Vice President and Chief Medical Officer. "We look forward to further understanding how vBloc performs in this population, as we continue to review long-term data derived from ReCharge and other vBloc studies."
I see some people questioning the PR. I think all names below have far to much to lose for some bs news.
John M. Morton, Sajani N. Shah, Bruce M. Wolfe, Caroline M. Apovian, Christopher J. Miller, Katherine S. Tweden , Charles J. Billington, Scott A. Shikora
Not hardly, I'm in it for the long haul, like you and IGXT. But you knew that!!
For some reason I can't get the link to post. The lady in this story started a blog which can be viewed At Florida Hospital Tampa website.
Here are a few things she said:
On January 27, 2016, I had my surgery. I could not be happier! Today it is six weeks and I have lost 17 pounds.
Myra’s vBloc Story: Why I Chose vBloc
Like 99% of people, I had tried every diet around, they would work for a while, but always were impossible to live with long term. I did consider gastric bypass
Yeah, it is something to complain about. I am not sure how long you been here but if you remember they delayed this after FDA approval. The board supposedly felt like milestones weren't met then. So other than Winthrop and few more surgeries what made them think the right time was now?
As for the "realstat-spence" comment, that is something they might say, you would be blind to think otherwise. What I got tired of was the nay-sayers who say the device doesn't work.
Kevin Douglas holding strong. I was wondering about him. I really hope someone reigns in compensation for these guys. Looks like they paid themselves well in February.
The Board of Directors approved bonus awards of $66,224, $13,274, $135,453, $53,075, $49,088, $42,286 and $41,700 for Dr. Knudson, Mr. Gladney, Mr. Lea, Dr. Shikora, Mr. Hancock, Mr. Donders and Dr. Tweden, respectively. These bonus awards were paid to the named executive officers in February 2016.
Additionally, pursuant to Amendment No. 2 to Mr. Lea’s employment agreement, discussed in further detail below under the heading “Employment Agreements,” Mr. Lea was deemed to have achieved 100% of the corporate performance objectives and individual performance objectives under the Management Incentive Plan and a 20% premium on his bonus for 2015. Also, based on his offer letter, Dr. Shikora was deemed to have achieved 100% of the corporate performance objectives.
I do understand the point you where trying to make. But again it is not outside the realm of possibility.
The messages on a message board should always be viewed with skepticism.
I do not drink anyone's "koolaid" but my own, it is potent. I have only once made a decision based entirely off what a poster has recommended who I think is very knowledgeable. Turned out he/she was right! The company was Mannkind which I did very well in getting in/out a the most opportune time. I would NEVER suggest anyone doing that.
You keep insinuating along with others I am, or have somehow been responsible for investors losing money here. Tell me what I have lied about or ever said to mislead investors? I am losing too.
I am invested in the company and will continue to be for the foreseeable future. It is just my style I guess to share things I find which are most generally related to the company, space, or technology. I know some don't like it calling it pumpery and that's fine. But there is an easy solution, it's the ignore tab.
Not sure about Gladney but it's not outside realm of possibility.
GlaxoSmithKline, the UK pharmaceutical company, is pioneering a different approach: so-called bioelectronics, or electroceuticals. These aim to turn our electrical impulses into a mainstay of medical treatment.
Kris Famm, head of bioelectronics research at GSK, says "scientists are learning how the electrical language of the body controls human organs in order to provide precision therapies. What we’ve learnt so far looks very promising,” he says.The aim is to develop products without the side effects of today’s drugs
Role of the vagus nerve in the development and treatment of diet-induced obesity
Well ETRM did get FDA approval for a device entering potentially a multi billion dollar market. They have no partner, enough cash for 1 year, and provider coverage has started.
You could say that with any company. You have to spend money to make money. Besides, I am just putting it out there for those interested as to what is going on.